Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nancy Pham

Digital Content Designer

Washington, DC

Nancy supports the Citeline editorial team with design and multimedia projects, including infographics, data visualizations, and UI/UX.

She holds a BA in Journalism and previously worked at US News & World Report as a digital producer. In her spare time, Nancy enjoys traveling, being outdoors, and attending concerts.

Latest From Nancy Pham

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.

Business Strategies Drug Approval Standards

IRA Litigation Landscape: Where The Cases Are And Where They Are Headed

Pink Sheet infographic details the district court judges and circuit courts that will be deciding the cases brought by industry against the IRA, breaking down the Democrat and Republican appointees as well as the arguments in each suit.

Medicare Legal Issues

Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List

The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.

United States Intellectual Property

Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List

The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.

Medicare Reimbursement

How Fast Is ‘Expedited’? Pepaxto To Show Speed Of New Withdrawal Process For Accelerated Approval Drugs

For the Pepaxto appeal to be wrapped up on a faster timeline than Genentech’s dispute with the US FDA drugs center over Avastin’s breast cancer claim, CBER Director Peter Marks, the commissioner’s designee, would have to render a final decision before January 2024.

Review Pathway Post Market Regulation & Studies

Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations

Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Pink Sheet's new chart tracks the developments.

Medicare Legal Issues
See All
UsernamePublicRestriction

Register